Claims for Patent: 5,914,111

Summary for Patent: 5,914,111

Title:	CD2-binding domain of lymphocyte function associated antigen-3
Abstract:	Polypeptides and proteins comprising the CD2-binding domain of LFA-3 are disclosed. DNA sequences that code on expression for those polypeptides and proteins, methods of producing and using those polypeptides and proteins, and therapeutic and diagnostic compositions are also disclosed. Deletion mutants unable to bind CD2 and methods for their use are also disclosed. In addition, fusion proteins which comprise the CD2-binding domain of LFA-3 and a portion of a protein other than LFA-3, DNA sequences encoding those fusion proteins, methods for producing those fusion proteins, and uses of those fusion proteins are disclosed.
Inventor(s):	Wallner; Barbara P. (Cambridge, MA), Miller; Glenn T. (Haverhill, MA), Rosa; Margaret D. (Winchester, MA)
Assignee:	Biogen Inc. (Cambridge, MA)
Application Number:	08/459,657
Patent Claims:	1. A method of inhibiting T-cell activation comprising administering to a population of T cells a polypeptide having amino terminal amino acids 1-92 of lymphocyte functioning associated antigen-3 (LFA-3) joined to a protein or polypeptide other than LFA-3, wherein the protein or polypeptide other than LFA-3 comprises a portion of hinge, C.sub.H 2 and C.sub.H 3 constant domains of an immunoglobulin. 2. A method of inhibiting T-cell activation comprising administering to a population of T cells a polypeptide having amino terminal amino acids 1-92 of lymphocyte functioning associated antigen-3 (LFA-3) and a portion of an Fc region of a human immunoglobulin IgG1 sufficient to be recognized by protein A. 3. The method of claim 2, wherein the Fc region comprises a hinge region that is capable of forming intermolecular disulfide bonds. 4. A method of inhibiting T-cell activation comprising administering to a population of T cells a polypeptide encoded by a DNA sequence contained in plasmid pSAB152 ATCC Accession Number 68720. 5. A method of inhibiting T-cell activation comprising administering to a population of T cells a polypeptide comprising amino acid residues 29-120 of of SEQ. ID. NO.:43 linked to an Fc portion of IgG. 6. The method of claim 5, wherein the Fc portion of IgG comprises amino acids 121-347 of SEQ ID NO.:43.

Details for Patent 5,914,111

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Astellas Pharma Us, Inc.	AMEVIVE	alefacept	For Injection	125036	01/30/2003		2016-06-22

International Patent Family for US Patent 5,914,111

Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	9216622
United States of America	5928643
United States of America	5728677
United States of America	5547853
Singapore	47766
Portugal	503648
Mexico	9203138